Dolutegravir in HIV-1 infection: Added benefit in adult patients

Added benefit based on fewer side effects/ no data for adolescents and pretreated adults who do not require integrase inhibitors

2014-05-21

(Press-News.org) Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) now examined whether the new drug offers an added benefit over the appropriate comparator therapy.

The dossier compiled by the drug manufacturer provided proof of a considerable added benefit in adults without pretreatment and an indication of a minor added benefit in pretreated adults who require integrase inhibitors (INIs) (i. e. whose treatment should include an INI). These patients have fewer side effects with the new drug than with the respective comparator therapy.

No added benefit could be determined for pretreated adults who do not require INIs (i. e. in whom no integrase inhibitor is indicated) and for adolescents above 12 years of age, because there were no study data.

Comparator therapy depends on pretreatment and age

Dolutegravir is a so-called integrase inhibitor (INI) and aims to prevent the integration of viral DNA into the nucleus of human cells. The Federal Joint Committee (G-BA) distinguished between adults and adolescents depending on the pretreatment, and specified different appropriate comparator therapies for the different patient groups:

In adults without pretreatment (treatment-naive), dolutegravir was to be compared with efavirenz (NNRTI drug class) in combination with two nucleoside/nucleotide analogues (NRTI drug class), tenofovir plus emtricitabine or abacavir plus lamivudine. In treatment-naive adolescents, the new drug was to be compared with efavirenz in combination with abacavir plus lamivudine.

For adolescents and adults who have already been treated for HIV-1 with other drugs, the G‑BA specified an individual antiretroviral treatment depending on their prior therapy and the reason for the treatment switch. Particularly treatment failure because of a lack of antiviral effect (possibly associated with resistance of the virus to some drugs) or side effects were relevant.

In case of resistance to other drug classes in pretreated patients, treatment should include a drug of a further drug class. When resistance to NRTIs or NNRTI has been proven, for example, an INI is a commonly chosen treatment.

Treatment-naive adults: considerable added benefit

Two randomized controlled trials (RCTs), SPRING-1 and SINGLE, with a study duration of 96 weeks each and a total of almost 1000 study participants, were included in the assessment. The results of these 2 studies showed no differences between the treatment groups with regard to mortality and morbidity.

Neither HIV symptoms nor the outcome "quality of life" was recorded in the SPRING-1 study, and the SINGLE study produced no evaluable data for these two outcomes. Hence an added benefit of dolutegravir is not proven for these patient-relevant outcome criteria.

Untreated adults had noticeably fewer side effects under dolutegravir, however: Study discontinuations due to side effects and skin rash occurred less frequently in both sexes, and in men, nervous system disorders were less common under treatment with dolutegravir.

As no indication of considerably worse results can be inferred from the data on morbidity in treatment-naive adults, proof of a considerable added benefit can be derived for dolutegravir in the overall assessment of the results on side effects.

Different comparator therapies depending on individual pretreatment

In the only study (SAILING) that investigated pretreated adults, dolutegravir was compared with another INI (raltegravir). The study participants were not pretreated with INIs and all of them had resistance to various drugs. They received dolutegravir or raltegravir in addition to an individual antiretroviral treatment, which depended on the respective resistance and which was already individually specified before randomization.

Pretreated adults requiring INI: minor added benefit

In pretreated adults with HIV-1 infection with mandatory INI treatment, the study groups in the SAILING study did not differ with regard to mortality and symptoms (morbidity). HIV symptoms were not recorded in the study, which also produced no evaluable data on quality of life. Hence no added benefit of dolutegravir can be determined for these patient-relevant outcomes.

However, dolutegravir had advantages with respect to side effects for patients who require INIs: Severe side effects like infection were less common, and nervous system disorders were also less frequent in patients over the age of 50 years. Overall, there is an indication of a minor added benefit of dolutegravir because there were fewer side effects than under the comparator therapy.

In contrast, no conclusions can be derived from the results of the SAILING study for pretreated patients in whom INI was possible but not mandatory.

No data on adolescents

As no study could be identified that investigated HIV-1 infected adolescents aged 12 years or older – neither treatment-naive nor pretreated – there were no data on the comparison of dolutegravir with the appropriate comparator therapy. Hence an added benefit of dolutegravir is not proven for adolescent patients.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G-BA decides on the extent of the added benefit, thus completing the early benefit assessment.

INFORMATION: An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website gesundheitsinformation.de, published by IQWiG, provides easily understandable and brief German-language information on dolutegravir.

The G-BA website contains both general English-language information on benefit assessments pursuant to §35a Social Code Book V and specific German-language information on the assessment of dolutegravir.

ELSE PRESS RELEASES FROM THIS DATE:

EORTC to present cancer research results at ASCO 2014

2014-05-21

The EORTC will present nine abstracts at the ASCO 2014 Annual Meeting which will be held 30 May – 03 June 2014 in Chicago, Illinois. Four abstracts will be presented in Oral Abstract Sessions, one in a Poster Highlights Session, and another four in General Poster Sessions. Oral Abstract Sessions Abstract # 4500 Monday, 02 June, 9:45 – 9:57, E Hall D1 Cora N. Sternberg, Iwona Skoneczna, J.M.Kerst, Sophie Fossa, Peter Albers, Mads Agerbaek, Herlinde Dumez, Maria De Santis, Christine Theodore, Michael Leahy, J.D. Chester, Antony Verbaeys, Armelle Caty, Gedske Daugaard, ...

The Net Children Go Mobile Project launches its report at the ICA 64th Annual Conference

2014-05-21

Washington, DC (May 21, 2014) The Net Children Go Mobile project will release new data on children's mobile use at the 64th Annual Conference of the International Communication Association at the Seattle Sheraton hotel. The project found that 46% of children own a smartphone and 41% use it daily to go online, while 20% own a tablet but 23% use it on a daily basis to access the Internet. Smartphone and tablet users engage more in communication and entertainment activities. They also have a higher level of digital skills, safety skills, and communicative abilities. However, ...

A star cluster in the wake of Carina

2014-05-21

NGC 3590 is a small open cluster of stars around 7500 light-years from Earth, in the constellation of Carina (The Keel). It is a gathering of dozens of stars loosely bound together by gravity and is roughly 35 million years old. This cluster is not just pretty; it is very useful to astronomers. By studying this particular cluster — and others nearby — astronomers can explore the properties of the spiral disc of our galaxy, the Milky Way. NGC 3590 is located in the largest single segment of a spiral arm that can be seen from our position in the galaxy: the Carina spiral ...

Study shows iron from melting ice sheets may help buffer global warming

2014-05-21

A newly-discovered source of oceanic bioavailable iron could have a major impact our understanding of marine food chains and global warming. A UK team has discovered that summer meltwaters from ice sheets are rich in iron, which will have important implications on phytoplankton growth. The findings are reported in the journal Nature Communications on 21st May, 2014*. It is well known that bioavailable iron boosts phytoplankton growth in many of the Earth's oceans. In turn phytoplankton capture carbon – thus buffering the effects of global warming. The plankton also feed ...

More maternal mental health surveillance is needed, suggests new study

2014-05-21

Maternal depression is more common at four years following childbirth than at any other time in the first 12 months after childbirth, and there needs to be a greater focus on maternal mental health, suggests a new study published today (21 May) in BJOG: An International Journal of Obstetrics and Gynaecology. The study using data from 1507 women from six public hospitals in Melbourne, Australia, examines the prevalence of maternal depression from early pregnancy to four years postpartum. The researchers identify the possible risk factors for depressive symptoms at four ...

Molecule linked to aggressive pancreatic cancer offers potential clinical advances

2014-05-21

JACKSONVILLE, Fla. — Mayo Clinic researchers have discovered an enzyme they say is tightly linked to how aggressive pancreatic cancer will be in a patient. They say the study, published in Molecular Cancer Research, provides key insights into the most aggressive form of the disease, which is one of the deadliest human cancers. It also offers a number of possible future clinical advances, such as a way to gauge outcome in individual patients, and insight into potential therapy to shut down activity of the enzyme, known as Rac1b. "The implication from our research is ...

A quicker way to determine who's faking it on the Internet

2014-05-21

Researchers at the University of Montreal have developed an improved chemical analysis method that is more efficient and faster in detecting counterfeit medicines, which have skyrocketed in recent years. The method was developed and tested in a study by Philippe Lebel, Alexandra Furtos and Karen Waldron of the university's Department of Chemistry. It identifies and quantifies the various compounds present in a pharmaceutical product, in a fifth of the time it takes governmental services to do the same job. "Fake drugs are a scourge for public health," says Lebel. Once a ...

Compound reverses symptoms of Alzheimer's disease in mice, SLU research shows

2014-05-21

ST. LOUIS -- A molecular compound developed by Saint Louis University scientists restored learning, memory and appropriate behavior in a mouse model of Alzheimer's disease, according to findings in the May issue of the Journal of Alzheimer's Disease. The molecule also reduced inflammation in the part of the brain responsible for learning and memory. The paper, authored by a team of scientists led by Susan Farr, Ph.D., research professor of geriatrics at Saint Louis University, is the second mouse study that supports the potential therapeutic value of an antisense compound ...

Vitamin E in canola and other oils hurts lungs

2014-05-20

CHICAGO --- A large new Northwestern Medicine® study upends our understanding of vitamin E and ties the increasing consumption of supposedly healthy vitamin E-rich oils -- canola, soybean and corn – to the rising incidence of lung inflammation and, possibly, asthma. The new study shows drastically different health effects of vitamin E depending on its form. The form of Vitamin E called gamma-tocopherol in the ubiquitous soybean, corn and canola oils is associated with decreased lung function in humans, the study reports. The other form of Vitamin E, alpha-tocopherol, ...

Researchers test whether Red Queen hypothesis makes species resilient

2014-05-20

In Lewis Carroll's 1871 classic novel Through the Looking Glass, the Red Queen tells Alice: "Now, here, you see, it takes all the running you can do, to keep in the same place." Over the years, evolutionary biologists have used the Red Queen's statement to refer to the "Red Queen" hypothesis, which describes how living organisms, including humans, manage to survive in a changing environment by adapting through sexual reproduction. According to a University of Iowa researcher, the hypothesis is supported. In a paper published in the journal Biology Letters, lead author ...

LAST 30 PRESS RELEASES:

Study unexpectedly finds living in rural, rather than urban environments in first five years of life could be a risk factor for developing type 1 diabetes